Abstract: Objective: To investigate the effect of sacubitril⁃valsartan on residual renal function (RRF) in patients with continuous ambulatory peritoneal dialysis (CAPD). Methodology: A retrospective analysis was conducted on 72 CAPD patients followed up in the Department of Nephrology of the First Affiliated Hospital of Anhui University of Chinese Medicine. Patients were divided into an observation group (n=34, taking sacubitril/valsartan) and a control group (n=38). The observation period was 12 months. General data, blood biochemistry, RRF indicators (24⁃hour residual urine volume, residual renal Kt/V, residual renal GFR), peritoneal Kt/V, total Kt/V, left ventricular ejection fraction (LVEF), brain natriuretic peptide (BNP), and adverse reactions were recorded. Results: There were no significant differences in baseline indicators between the two groups. During follow⁃up, RRF indicators of both groups decreased; except for residual renal Kt/V, there were significant group×time interaction effects (P interaction <0.05). The observation group had significantly higher residual renal Kt/V than the control group (P=0.041). For cardiac function, there was a significant interaction effect on LVEF (P interaction=0.005), and BNP in the observation group was significantly lower (P<0.001). For blood biochemical indicators, there were significant interaction effects on parathyroid hormone and blood phosphorus (P interaction <0.01), with lower values in the observation group after 12 months. Two cases of dry cough (5.9%) occurred in the observation group, and two cases of angioedema (5.6%) in the control group. Conclusion: Sacubitril⁃valsartan can effectively delay the loss of RRF, improve cardiac function, and reduce serum phosphorus levels in CAPD patients.

Key words: Sacubitril/valsartan, continuous ambulatory peritoneal dialysis, residual renal function